t
Proteome Sciences plc announced on 30 August 2023 that Chief Executive Officer, Dr Mariola Soehngen, will provide a live investor presentation related to the Half Year Results. This presentation is scheduled for 19th September 2023 at 10:00 am BST via the Investor Meet Company platform. The event is open to all existing and potential shareholders.
| Date | 30 Aug 2023 |
| Time | 14:14:25 |
| Category | Miscellaneous |
| ID | 8439K |
REACH: non-regulatory announcement*
30 August 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Investor Presentation
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Half Year Results via the Investor Meet Company platform on 19th Sep 2023 at 10:00am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Proteome Sciences plc via:
https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
Investors who already follow Proteome Sciences plc on the Investor Meet Company platform will automatically be invited.
|
For further information please contact:
Proteome Sciences plc |
||
|
Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer |
Tel: +44 (0)20 7043 2116 |
|
|
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer |
|
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser & Broker) |
|
|
|
John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking) |
Tel: +44 (0) 20 3328 5656
|
|
|
|
||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
*About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.